Literature DB >> 23477743

Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study.

Sander J Robins1, Asya Lyass, Robert W Brocia, Joseph M Massaro, Ramachandran S Vasan.   

Abstract

OBJECTIVE: Cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) are two genetically-related plasma proteins involved in the exchange of cholesteryl esters and phospholipids between high-density lipoproteins (HDL) and other lipoproteins. Although low CETP and high PLTP activity both result in higher concentrations of plasma HDL-cholesterol (HDL-C), there is no evidence that either of these changes is associated with a decrease in cardiovascular disease (CVD) in a general population.
METHODS: Plasma CETP and PLTP activities, measured by homogenous fluorometric assays using synthetic donor particle substrates, were related to the incidence of a first CVD event in Framingham Heart Study Offspring participants without CVD (n = 2679, mean age 59 y, 56% women) attending the 6th examination cycle (1995-98). Because of an effect modification by sex for both CETP and PLTP, analyzes were stratified by sex.
RESULTS: During follow-up (mean 10.4 years) 187 participants experienced a first CVD event. In sex-specific Cox models, both CETP and PLTP as continuous and as binary variables were associated with significantly increased CVD in men, but not women. In men compared to a referent group with CETP ≥ median and PLTP < median, the multivariable-adjusted hazard ratio (HR) for new CVD events was significantly greater with either the combination of high CETP and high PLTP (HR 2.27, 95% CI 1.23-4.20); low CETP and low PLTP (HR 2.23, 95% CI 1.19-4.17); or low CETP and high PLTP (HR 2.85, 95% CI 1.53-5.31). In contrast, in women the multivariable-adjusted HR for new CVD events was non-significant and virtually equal to "1.0" with all combinations of high and low CETP or PLTP values.
CONCLUSIONS: Lower plasma CETP or higher PLTP activity was each associated with a significantly increased risk of CVD. Inexplicably, the increase in CVD associated with both lipid transfer proteins was confined to men.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23477743      PMCID: PMC3692011          DOI: 10.1016/j.atherosclerosis.2013.01.046

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

1.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

2.  The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein.

Authors:  N Settasatian; M Duong; L K Curtiss; C Ehnholm; M Jauhiainen; J Huuskonen; K A Rye
Journal:  J Biol Chem       Date:  2001-04-26       Impact factor: 5.157

3.  Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency.

Authors:  X C Jiang; S Qin; C Qiao; K Kawano; M Lin; A Skold; X Xiao; A R Tall
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

4.  Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta-HDL generation.

Authors:  S Jaari; K W van Dijk; V M Olkkonen; A van der Zee; J Metso; L Havekes; M Jauhiainen; C Ehnholm
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2001-04       Impact factor: 2.231

5.  Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice.

Authors:  R van Haperen; A van Tol; P Vermeulen; M Jauhiainen; T van Gent; P van den Berg; S Ehnholm; F Grosveld; A van der Kamp; R de Crom
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

6.  Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.

Authors:  S Matthijs Boekholdt; Jan-Albert Kuivenhoven; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Robert Luben; Sheila A Bingham; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

7.  Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans.

Authors:  Charles C Schwartz; Julie M VandenBroek; Patricia S Cooper
Journal:  J Lipid Res       Date:  2004-05-16       Impact factor: 5.922

8.  Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.

Authors:  Ronald W Clark; Tamara A Sutfin; Roger B Ruggeri; Ann T Willauer; Eliot D Sugarman; George Magnus-Aryitey; Patricia G Cosgrove; Thomas M Sand; Ronald T Wester; John A Williams; Michael E Perlman; Mark J Bamberger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-01-22       Impact factor: 8.311

9.  High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease.

Authors:  Axel Schlitt; Christoph Bickel; Prathima Thumma; Stefan Blankenberg; Hans J Rupprecht; Juergen Meyer; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-08-28       Impact factor: 8.311

10.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

View more
  28 in total

1.  PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity.

Authors:  Daniel Seung Kim; Amber A Burt; Jane E Ranchalis; Simona Vuletic; Tomas Vaisar; Wan-Fen Li; Elisabeth A Rosenthal; Weijiang Dong; Jason F Eintracht; Arno G Motulsky; John D Brunzell; John J Albers; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2015-05-25       Impact factor: 5.922

Review 2.  Cholesteryl Ester Transfer Protein Inhibitors - Future Soon to be REVEALed.

Authors:  Christopher Huggins; Nicoletta Charolidi; Gillian W Cockerill
Journal:  Eur Cardiol       Date:  2015-07

3.  Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes.

Authors:  Hussein N Yassine; Alexandra Belopolskaya; Christina Schall; Craig S Stump; Serrine S Lau; Peter D Reaven
Journal:  Metabolism       Date:  2014-03-05       Impact factor: 8.694

Review 4.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 5.  Impact of Phospholipid Transfer Protein in Lipid Metabolism and Cardiovascular Diseases.

Authors:  Xian-Cheng Jiang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Dialysis Modalities and HDL Composition and Function.

Authors:  Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2015-03-05       Impact factor: 10.121

7.  Plasma Phospholipid Transfer Protein Promotes Platelet Aggregation.

Authors:  Xiao-Min Zhao; Yun Wang; Yang Yu; Hui Jiang; Anna Babinska; Xiu-Yu Chen; Ke-Gui He; Xiang-Dong Min; Ji-Ju Han; Chen-Xi Yang; Kevin Deng; Jing Xue; Xiangjian Zhang; Guo-Hua Song; Shu-Cun Qin; Xian-Cheng Jiang
Journal:  Thromb Haemost       Date:  2018-11-12       Impact factor: 5.249

Review 8.  Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis.

Authors:  Xian-Cheng Jiang
Journal:  J Lipid Res       Date:  2018-02-08       Impact factor: 5.922

9.  Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport.

Authors:  Takashi Kuwano; Xin Bi; Eleonora Cipollari; Tomoyuki Yasuda; William R Lagor; Hannah J Szapary; Junichiro Tohyama; John S Millar; Jeffrey T Billheimer; Nicholas N Lyssenko; Daniel J Rader
Journal:  J Lipid Res       Date:  2017-01-30       Impact factor: 5.922

10.  Phospholipid transfer protein deficiency decreases the content of S1P in HDL via the loss of its transfer capability.

Authors:  Yang Yu; Shoudong Guo; Yumei Feng; Lei Feng; Yingjie Cui; Guohua Song; Tian Luo; Ke Zhang; Yiwei Wang; Xian-Cheng Jiang; Shucun Qin
Journal:  Lipids       Date:  2013-10-25       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.